Research Article

Applications of Bioinformatics in Cervical Cancer Detection and Management With The Help of Artificial Intelligence

Divya Sachan[1*], Prof. Vishwas Dubey[2], Dr. Subhi Gupta[3], Dr. Neelam Choubey[4], Safalta Bidua[5], Dr. Varsha Bhargava[6]

[1]PhD Research Scholar,Vikrant University, Gwalior (MP)
[2]Assistant Professor, Vikrant University, Gwalior (MP)
[3]Junior Resident, Amalltas Institute of Medical Sciences, Dewas, Indore (MP)
[4]Assistant Professor, Vikrant University, Gwalior (MP)
[5]Research Scholar,Vikrant University, Gwalior (MP)
[6]Varsha Bhargava[6], PhD Scholar,Vikrant University, Gwalior (MP)

*Corresponding Author:- Divya Sachan, PhD Research Scholar,Vikrant University, Gwalior (MP)

Abstract

Cervical cancer remains a major global health concern, particularly in low- and middle-income countries, despite the availability of screening programs and prophylactic human papillomavirus (HPV) vaccination. Conventional diagnostic methods such as Pap smear cytology and HPV DNA testing are limited by subjective interpretation, variable sensitivity in early-stage lesions, and insufficient capability for personalized disease management. In this context, the integration of bioinformatics and artificial intelligence (AI**)** has emerged as a powerful paradigm for improving cervical cancer detection, prognosis, and clinical decision-making through the analysis of large-scale biological, imaging, and clinical datasets.

This review provides a comprehensive overview of recent advances in AI-driven bioinformatics applications for cervical cancer management, including genomic and transcriptomic analyses for biomarker discovery, proteomic and metabolomic profiling for early diagnosis, deep learning–based interpretation of cytology and histopathology images, and integrative multi-omics approaches for predicting disease progression and therapeutic response. Although these technologies have demonstrated promising diagnostic accuracy and predictive performance in research settings, their translation into routine clinical practice remains limited.

A critical limitation in AI-driven bioinformatics for cervical cancer is the lack of large, standardized, and ethnically diverse multi-modal datasets, which restricts model training, validation, and reliable application across diverse populations.

Keywords: Cervical cancer, Human papillomavirus (HPV), Bioinformatics, Artificial intelligence (AI), Machine learning, Deep learning

Introduction

Cervical cancer is one of the most common malignancies affecting women worldwide and remains a leading cause of cancer-related mortality, particularly in low- and middle-income countries (LMICs). According to global cancer statistics, a substantial proportion of cervical cancer cases and deaths occur in regions with limited access to effective screening, early diagnosis, and advanced treatment facilities. Although the introduction of organized screening programs and prophylactic vaccination against human papillomavirus (HPV) has significantly reduced disease incidence in high-income countries, cervical cancer continues to pose a major public health challenge on a global scale.

Persistent infection with high-risk HPV genotypes, especially HPV-16 and HPV-18, is well established as the primary etiological factor in cervical carcinogenesis. HPV-driven oncogenesis involves viral integration into the host genome and dysregulation of key cellular pathways controlling cell cycle progression, apoptosis, and genomic stability. While most HPV infections are transient and cleared by the immune system, a subset of infections persists and progresses through precancerous stages to invasive cancer. Early identification of high-risk lesions is therefore critical for effective disease prevention and management.

Conventional cervical cancer screening strategies, including Pap smear cytology, HPV DNA testing, and visual inspection with acetic acid (VIA), have contributed substantially to early detection and reduced mortality. However, these approaches suffer from several limitations. Cytology-based screening is labor-intensive and prone to inter- and intra-observer variability, while HPV testing lacks specificity in distinguishing transient infections from clinically significant lesions. Moreover, these traditional methods provide limited molecular insight into disease heterogeneity and are insufficient for personalized risk assessment, prognosis, and treatment planning.

In recent years, advances in high-throughput technologies have generated vast amounts of biological data, including genomics, transcriptomics, epigenomics, proteomics, and metabolomics, collectively referred to as “omics” data. Bioinformatics plays a crucial role in managing, integrating, and interpreting these complex datasets to uncover molecular mechanisms underlying cervical cancer

initiation and progression. Bioinformatics-driven analyses have facilitated the identification of novel biomarkers, dysregulated signaling pathways, and potential therapeutic targets associated with HPV-associated malignancies.

Parallel to these developments, artificial intelligence (AI)—particularly machine learning (ML) and deep learning (DL)—has gained increasing attention in biomedical research and clinical oncology. AI algorithms are capable of learning complex, non-linear patterns from large and heterogeneous datasets, making them particularly suitable for cancer detection, classification, and prediction tasks. In cervical cancer research, AI has been successfully applied to automated analysis of cytology and histopathology images, prediction of HPV persistence, identification of molecular signatures, and estimation of treatment response and patient survival.

The integration of AI with bioinformatics has given rise to powerful computational frameworks capable of combining molecular, imaging, and clinical data into unified analytical models. Such integrative approaches hold significant promise for improving early detection accuracy, reducing diagnostic subjectivity, enabling precision medicine, and supporting clinical decision-making. Despite these advances, the clinical translation of AI-enabled bioinformatics tools for cervical cancer remains limited. Challenges related to data quality, dataset heterogeneity, lack of standardized workflows, limited model interpretability, and insufficient external validation continue to impede real-world implementation.

Given the rapid growth of research in this interdisciplinary field, a comprehensive and critical review is necessary to synthesize current knowledge, evaluate methodological strengths and limitations, and identify unresolved challenges. Therefore, this review aims to systematically examine the applications of bioinformatics and artificial intelligence in cervical cancer detection and management, with a particular focus on screening, diagnosis, prognosis, and therapeutic decision support.

2. Bioinformatics-Driven Molecular Insights into Cervical Cancer

2.1 Genomic Landscape and HPV-Associated Molecular Alterations

Persistent infection with high-risk human papillomavirus (HR-HPV) is the central etiological driver of cervical cancer, yet malignant transformation requires the accumulation of host genomic alterations. Large-scale sequencing efforts have revealed recurrent somatic mutations, copy number variations, and chromosomal rearrangements that cooperate with viral oncogenesis. The integrated genomic analysis conducted by the Cancer Genome Atlas (TCGA) Research Network identified frequent alterations in PIK3CA, EP300, FBXW7, PTEN, and STK11, implicating aberrant PI3K/AKT signaling and chromatin remodeling in cervical tumorigenesis (Cancer Genome Atlas Research Network, 2017).

Bioinformatics pipelines enable comprehensive characterization of HPV integration events, which often occur near oncogenes or fragile chromosomal regions, leading to genomic instability and deregulated gene expression. Computational tools such as Viral Fusion Seq and HPV Detector have demonstrated that HPV integration is associated with aggressive disease phenotypes and poor clinical outcomes (Tang et al., 2020). These findings underscore the importance of integrative genomic analyses for identifying molecular subtypes with distinct prognostic and therapeutic implications.

2.2 Epigenomic Dysregulation and DNA Methylation Signatures

Epigenetic modifications represent early and potentially reversible events in cervical carcinogenesis. DNA methylation changes, particularly promoter hypermethylation of tumor suppressor genes, have been consistently observed during the transition from precancerous lesions to invasive carcinoma. Genes such as CADM1, MAL, DAPK1, and FAM19A4 have emerged as robust methylation biomarkers associated with high-grade cervical intraepithelial neoplasia (CIN) and cancer progression (Wentzensen et al., 2016).

Bioinformatics-based methylation analyses facilitate the identification of disease-specific epigenetic signatures with higher specificity than HPV DNA testing alone. Clarke et al. (2018) demonstrated that host and viral DNA methylation markers significantly improve triage accuracy for HPV-positive women, reducing unnecessary colposcopies. These findings highlight the clinical potential of epigenomic biomarkers for risk-based screening and early intervention.

2.2 Epigenomic Dysregulation and DNA Methylation Signatures

Epigenetic modifications represent early and potentially reversible events in cervical carcinogenesis. DNA methylation changes, particularly promoter hypermethylation of tumor suppressor genes, have been consistently observed during the transition from precancerous lesions to invasive carcinoma. Genes such as CADM1, MAL, DAPK1, and FAM19A4 have emerged as robust methylation biomarkers associated with high-grade cervical intraepithelial neoplasia (CIN) and cancer progression (Wentzensen et al., 2016).

Bioinformatics-based methylation analyses facilitate the identification of disease-specific epigenetic signatures with higher specificity than HPV DNA testing alone. Clarke et al. (2018) demonstrated that host and viral DNA methylation markers significantly improve triage accuracy for HPV-positive women, reducing unnecessary colposcopies. These findings highlight the clinical potential of epigenomic biomarkers for risk-based screening and early intervention.

2.3 Transcriptomic Profiling and Regulatory RNA Networks

Transcriptomic analyses using RNA sequencing have provided critical insights into gene expression dysregulation associated with cervical cancer progression. Differential expression studies have identified pathways related to immune evasion, angiogenesis, epithelial–mesenchymal transition (EMT), and cell cycle regulation as key drivers of tumor aggressiveness (Scotto et al., 2008).

Beyond protein-coding genes, non-coding RNAs play essential regulatory roles in cervical cancer biology. MicroRNAs such as miR-21,

miR-34a, and miR-155 have been implicated in HPV-mediated oncogenic signaling and immune modulation, while long non-coding RNAs including HOTAIR, MALAT1, and PVT1 contribute to chromatin remodeling and transcriptional control (Wang et al., 2019; Peng et al., 2017). Bioinformatics-driven network analyses enable the construction of competing endogenous RNA networks, offering novel insights into post-transcriptional regulation and potential therapeutic targets.

3. Artificial Intelligence Applications in Cervical Cancer Screening and Diagnosis

3.1 Deep Learning-Based Cytology and Histopathology Analysis

Artificial intelligence, particularly deep learning using convolutional neural networks (CNNs), has shown substantial promise in automating cervical cancer screening and diagnosis. AI-based systems have achieved high accuracy in detecting abnormal cells and classifying cervical intraepithelial neoplasia (CIN) grades from Pap smear images, often matching or exceeding expert cytopathologist performance (Zhang et al., 2020).

Similarly, deep learning models applied to whole-slide histopathology images enable automated tumor detection, grading, and segmentation, reducing inter-observer variability and improving diagnostic consistency (Guan et al., 2021). These approaches are particularly relevant in low-resource settings, where shortages of trained personnel limit screening coverage.

3.2 Machine Learning-Driven HPV Risk Stratification

Machine learning models integrating viral, host, and clinical features have been developed to predict HPV persistence and progression risk. Unlike conventional HPV testing, which lacks specificity, AI-driven risk stratification distinguishes transient infections from those likely to progress to high-grade lesions or cancer (Kitchener et al., 2018). Such models support personalized screening intervals and targeted follow-up, optimizing resource utilization while minimizing patient burden.

3.3 Prognostic Modeling and Therapeutic Response Prediction

AI-based prognostic models have demonstrated utility in predicting survival outcomes, recurrence risk, and treatment response in cervical cancer patients. By integrating multi-modal data—including molecular profiles, radiomic features, and clinical variables—machine learning algorithms generate individualized risk predictions that support precision oncology (Ayer et al., 2016). Radiomics combined with AI further enables non-invasive assessment of tumor heterogeneity and treatment response, particularly in radiotherapy planning (Lambin et al., 2017).

4. Integrative Multi-Omics and AI-Enabled Clinical Decision Support

The complexity of cervical cancer arises from the dynamic interplay between viral oncogenesis, host genomic instability, epigenetic dysregulation, immune modulation, and tumor microenvironmental factors. Single-omics approaches provide valuable but inherently limited snapshots of this multifactorial disease. Integrative multi-omics strategies, combined with artificial intelligence (AI), offer a holistic framework for deciphering cervical cancer biology and translating molecular insights into clinically actionable decision support systems.

4.1 Rationale for Multi-Omics Integration in Cervical Cancer

Cervical carcinogenesis is driven by coordinated alterations across multiple biological layers, including genomic mutations, epigenomic modifications, transcriptomic reprogramming, proteomic remodeling, and metabolic reorganization. High-risk HPV infection acts as an initiating event, but host-specific molecular responses ultimately determine disease progression, therapeutic response, and clinical outcome. Consequently, reliance on a single data modality fails to capture tumor heterogeneity and limits predictive accuracy.

Multi-omics integration enables the identification of convergent molecular pathways and regulatory networks underlying disease phenotypes. For instance, genomic alterations in PIK3CA may be reflected at the transcriptomic and proteomic levels through dysregulated PI3K/AKT signaling, while epigenetic silencing of tumor suppressor genes may manifest as altered gene expression and downstream metabolic changes. Integrative analyses therefore provide a systems-level understanding essential for precision oncology (Subramanian et al., 2020).

4.2 Multi-Omics Data Types and Analytical Frameworks

4.2.1 Genomics and Epigenomics Integration

Integration of genomic and epigenomic data has proven particularly informative in cervical cancer. Somatic mutations and copy number variations interact with DNA methylation and chromatin accessibility to regulate oncogene activation and tumor suppressor inactivation. Bioinformatics frameworks such as iCluster and MOFA (Multi-Omics Factor Analysis) enable joint modeling of genomic and epigenomic datasets to identify latent molecular subtypes with distinct clinical outcomes (Argelaguet et al., 2018).

In cervical cancer, combined analysis of HPV integration patterns and host DNA methylation profiles has improved risk stratification for high-grade lesions and invasive disease, offering potential triage tools for HPV-positive populations (Clarke et al., 2018).

4.2.2 Transcriptomics, Proteomics, and Metabolomics Coupling

Transcriptomic data provide insights into gene expression dynamics, while proteomic and metabolomic data reflect functional cellular states. Integrative analyses linking mRNA expression with protein abundance and metabolic alterations reveal post-transcriptional

regulation and pathway activity not captured by transcriptomics alone.

In cervical cancer, integration of transcriptomic and proteomic data has identified dysregulated immune response pathways and metabolic reprogramming associated with tumor aggressiveness and therapy resistance (Zhang et al., 2013; Hasim et al., 2013). Network-based bioinformatics approaches, including weighted gene co-expression network analysis (WGCNA), facilitate the identification of key driver modules across omics layers.

4.3 Role of Artificial Intelligence in Multi-Omics Integration

4.3.1 Machine Learning and Deep Learning Architectures

The high dimensionality, heterogeneity, and complexity of multi-omics datasets necessitate advanced AI methodologies. Machine learning algorithms such as random forests, support vector machines, and elastic net regression have been widely used for feature selection and classification tasks. However, deep learning models, including autoencoders, deep neural networks (DNNs), and graph neural networks (GNNs), are increasingly favored for their ability to learn hierarchical and non-linear representations of integrated omics data.

Autoencoder-based architectures enable dimensionality reduction and latent feature extraction, facilitating disease subtyping and outcome prediction. In cervical cancer, deep learning-driven multi-omics models have demonstrated superior performance in predicting disease progression and survival compared to single-omics approaches (Chaudhary et al., 2018).

4.3.2 Explainable AI for Clinical Trust

Despite their predictive power, AI models often function as "black boxes," limiting clinical interpretability and adoption. Explainable AI (XAI) techniques, such as SHAP (Shapley Additive Explanations) and LIME (Local Interpretable Model-agnostic Explanations), are increasingly integrated into multi-omics frameworks to identify key molecular drivers influencing model predictions. In cervical cancer, XAI approaches can highlight clinically relevant biomarkers, such as methylation markers or immune-related genes, enhancing clinician trust and supporting regulatory approval processes.

4.4 AI-Enabled Clinical Decision Support Systems (CDSS)

4.4.1 Screening and Risk Stratification

AI-enabled CDSS integrating multi-omics and clinical data facilitate personalized risk assessment for HPV-positive women. These systems can stratify patients based on progression risk, enabling tailored screening intervals and targeted interventions. Integration of molecular biomarkers with cytology and imaging data further enhances screening accuracy, reducing both false positives and false negatives (Kitchener et al., 2018).

4.4.2 Prognosis and Therapeutic Decision-Making

Multi-omics-based AI models support prognostic assessment by predicting survival outcomes, recurrence risk, and treatment response. For example, integrating genomic alterations, immune gene expression profiles, and radiomic features enables identification of patients likely to benefit from chemoradiotherapy or emerging immunotherapies.

AI-driven CDSS provide clinicians with evidence-based recommendations, facilitating precision treatment planning while accounting for tumor heterogeneity and patient-specific factors (Lambin et al., 2017).

Table 1. Bioinformatics and Artificial Intelligence Applications in Cervical Cancer Detection and Management

Domain	Data Type / Modality	Computational Approach	Key Applications	Representative Findings / Advantages	Limitations & Challenges
Genomics	Whole-exome/whole-genome sequencing, HPV integration data	Bioinformatics pipelines, variant calling, fusion detection	Identification of driver mutations, HPV integration sites, molecular subtypes	Recurrent alterations in PIK3CA, EP300, FBXW7; HPV integration linked to aggressive phenotypes	Limited cohort size, population bias, lack of longitudinal data
Epigenomics	DNA methylation (host and viral)	Differential methylation analysis, ML-based classifiers	Early detection, risk stratification, triage of HPV-positive women	Methylation markers (CADM1, MAL, FAM19A4) improve specificity over HPV testing alone	Standardization of assays, clinical validation
Transcriptomics	RNA-seq, miRNA, lncRNA profiles	Differential expression, network	Pathway discovery,	Dysregulation of EMT, immune	Batch effects, tissue

		analysis, AI feature selection	prognostic biomarkers, immune profiling	evasion pathways; regulatory RNA networks identified	heterogeneity
Cytology Imaging	Pap smear images	Deep learning (CNNs)	Automated screening, CIN grading	Diagnostic accuracy comparable or superior to expert cytopathologists	Need for large annotated datasets, regulatory approval
Multi-Omics Integration	Genomics, epigenomics, transcriptomics, proteomic	Autoencoders, MOFA, GNNs	Disease subtyping, survival prediction, precision oncology	Superior predictive performance vs. single-omics approaches	Data integration complexity, overfitting risk
Clinical Decision Support Systems (CDSS)	Omics, imaging, clinical data	AI-driven risk models, explainable AI	Personalized screening, prognosis, therapy selection	Supports evidence-based, individualized care	Lack of prospective validation, ethical and regulatory concerns

Future Directions

Cervical cancer remains a substantial global health challenge despite the availability of effective screening strategies and prophylactic human papillomavirus vaccination. The disease is driven by persistent high-risk HPV infection, yet its progression is governed by complex, multi-layered molecular alterations encompassing genomic instability, epigenetic dysregulation, transcriptomic reprogramming, proteomic remodeling, and metabolic reorganization. Conventional diagnostic and screening approaches provide limited insight into this biological complexity and are insufficient for individualized risk assessment and precision treatment planning. In recent years, the convergence of bioinformatics and artificial intelligence (AI) has introduced powerful computational strategies for addressing these limitations. Bioinformatics analyses of high-throughput multi-omics data have facilitated the discovery of molecular biomarkers, dysregulated signaling pathways, and potential therapeutic targets associated with cervical cancer initiation and progression. In parallel, AI-based models—particularly those employing machine learning and deep learning—have demonstrated strong performance in automated cytology and histopathology interpretation, HPV risk stratification, prognostic modeling, and prediction of therapeutic response. Integrative multi-omics frameworks supported by AI offer a systems-level perspective of cervical cancer biology and form the foundation for next-generation clinical decision support systems.

Despite these advances, the translation of AI-driven bioinformatics approaches into routine clinical practice remains limited. Key barriers include the scarcity of large, standardized, and ethnically diverse datasets; methodological challenges related to model overfitting and limited external validation; insufficient interpretability of complex AI models; and unresolved ethical, regulatory, and infrastructural constraints. Furthermore, the predominance of retrospective study designs and the lack of prospective clinical validation limit the current clinical impact of these technologies.

Future progress in this field will require a strategic shift toward clinically oriented research and implementation. Priority should be given to the generation of large-scale, longitudinal, and globally representative multi-omics datasets through international collaboration. Standardization of data acquisition, integration, and reporting workflows is essential to ensure reproducibility and facilitate regulatory evaluation. Equally important is the development of explainable and clinically interpretable AI models that enhance transparency, foster clinician trust, and support regulatory approval. Prospective multi-center clinical trials and real-world validation studies are urgently needed to demonstrate clinical utility, cost-effectiveness, and patient benefit.

Importantly, future innovation must be aligned with global health equity. Given the disproportionate burden of cervical cancer in low- and middle-income countries, AI-enabled tools should be designed with scalability, affordability, and minimal infrastructure requirements in mind. Ethical-by-design principles, robust data governance, and bias mitigation strategies must be embedded throughout the development and deployment lifecycle to ensure responsible and equitable implementation.

Conclusion

In conclusion, the integration of bioinformatics and artificial intelligence represents a promising pathway toward improved cervical cancer detection, prognosis, and personalized management. While substantial methodological progress has been achieved, realizing

the full clinical potential of these technologies will require sustained interdisciplinary collaboration, rigorous validation, and ethical stewardship. With these foundations in place, AI-driven bioinformatics has the capacity to contribute meaningfully to reducing the global burden of cervical cancer and advancing precision oncology.

References

1. Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer. Nature, 543(7645), 378–384 (2017).
2. Tang, K. W., Alaei-Mahabadi, B., Samuelsson, T., Lindh, M., Larsson, E. The landscape of viral expression and host gene fusion and adaptation in human cancer. Nature Communications, 11, 1003 (2020).
3. Wentzensen, N., Clarke, M. A., Perkins, R. B. Impact of HPV genotyping and methylation markers on cervical cancer screening. Journal of the National Cancer Institute, 108(1) (2016).
4. Clarke, M. A., et al. Human papillomavirus DNA methylation as a biomarker for cervical precancer: A systematic review and meta-analysis. Cancer Epidemiology, Biomarkers & Prevention, 27(5), 505–515 (2018).
5. Scotto, L., et al. Differential gene expression profiles in cervical cancer progression. Molecular Cancer, 7, 29 (2008).
6. Wang, Y., et al. Long non-coding RNAs in cervical cancer: Biological functions and clinical implications. Molecular Cancer, 18, 38 (2019).
7. Peng, L., Yuan, X., Jiang, B., Tang, Z., Li, G. LncRNAs: Key players and novel insights into cervical cancer. Tumor Biology, 39(6) (2017).
8. Zhang, L., et al. Deep learning-based classification of cervical cytology images. IEEE Journal of Biomedical and Health Informatics, 24(4), 1163–1174 (2020).
9. Guan, Q., et al. Deep learning-based histopathological image analysis for cervical cancer diagnosis. Computers in Biology and Medicine, 132, 104319 (2021).
10. Kitchener, H. C., et al. HPV testing in routine cervical screening: Cross-sectional and longitudinal analyses. The Lancet Oncology, 19(5), 560–569 (2018).
11. Ayer, T., et al. Machine learning in clinical decision support for oncology. Journal of Biomedical Informatics, 63, 1–10 (2016).
12. Lambin, P., et al. Radiomics: The bridge between medical imaging and personalized medicine. Nature Reviews Clinical Oncology, 14(12), 749–762 (2017).
13. Subramanian, I., et al. Multi-omics data integration, interpretation, and its application. Briefings in Bioinformatics, 21(4), 1319–1331 (2020).
14. Argelaguet, R., et al. Multi-Omics Factor Analysis—a framework for unsupervised integration of multi-omics data. Molecular Systems Biology, 14(6), e8124 (2018).
15. Zhang, B., et al. Proteogenomic characterization of human cancers. Nature, 513(7518), 382–387 (2013).
16. Hasim, A., et al. Metabolomic profiling of cervical cancer: Biomarkers for early detection. Journal of Proteome Research, 12(2), 897–905 (2013).
17. Chaudhary, K., Poirion, O. B., Lu, L., Garmire, L. X. Deep learning-based multi-omics integration robustly predicts survival in cancer. Clinical Cancer Research, 24(6), 1248–1259 (2018).
18. World Health Organization (WHO). Global strategy to accelerate the elimination of cervical cancer as a public health problem. WHO, Geneva (2020).
19. Arbyn, M., et al. Estimates of incidence and mortality of cervical cancer worldwide. The Lancet Global Health, 8(2), e191–e203 (2020).
20. Esteva, A., et al. A guide to deep learning in healthcare. Nature Medicine, 25(1), 24–29 (2019).
21. Topol, E. J. High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25, 44–56 (2019).
22. He, B., et al. Multi-omics profiling in HPV-associated cancers. Frontiers in Oncology, 11, 642701 (2021).
23. Yu, K. H., Beam, A. L., Kohane, I. S. Artificial intelligence in healthcare. Nature Biomedical Engineering, 2, 719–731 (2018).
24. Litjens, G., et al. A survey on deep learning in medical image analysis. Medical Image Analysis, 42, 60–88 (2017).
25. McKinney, S. M., et al. International evaluation of an AI system for cancer screening. Nature, 577, 89–94 (2020).
26. Schiffman, M., Doorbar, J., Wentzensen, N., de Sanjosé, S., Fakhry, C., Monk, B. J., Stanley, M. A., Franceschi, S. Carcinogenic human papillomavirus infection. Nature Reviews Disease Primers, 2, 16086 (2016).
27. Arbyn, M., Smith, S. B., Temin, S., Sultana, F., Castle, P. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples. CA: A Cancer Journal for Clinicians, 68(1), 7–28 (2018).
28. Crosbie, E. J., Einstein, M. H., Franceschi, S., Kitchener, H. C. Human papillomavirus and cervical cancer. The Lancet, 382(9895), 889–899 (2013).
29. Rajpurkar, P., Chen, E., Banerjee, O., Topol, E. J. AI in health and medicine. Nature Medicine, 28, 31–38 (2022).
30. Kourou, K., Exarchos, T. P., Exarchos, K. P., Karamouzis, M. V., Fotiadis, D. I. Machine learning applications in cancer prognosis and prediction. Computational and Structural Biotechnology Journal, 13, 8–17 (2015).

31. Zhao, M., Chen, Z., Zheng, Y., Liu, Y. Machine learning-based cervical cancer risk prediction using clinical and molecular data. BMC Medical Informatics and Decision Making, 21, 52 (2021).
32. Wang, S., Yang, D. M., Rong, R., Zhan, X., Xiao, G. Pathology image analysis using segmentation deep learning algorithms. The American Journal of Pathology, 189(9), 1686–1698 (2019).
33. Gevaert, O., Mitchell, L. A., Achrol, A. S., et al. Glioblastoma multiforme: Exploratory radiogenomic analysis by integrating clinical, molecular, and imaging features. Radiology, 273(1), 168–174 (2014).
34. Reel, P. S., Reel, S., Pearson, E., Trucco, E., Jefferson, E. Using machine learning approaches for multi-omics data analysis: A review. Biotechnology Advances, 39, 107547 (2021).